These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 20805365)

  • 1. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.
    Schnittger S; Haferlach C; Ulke M; Alpermann T; Kern W; Haferlach T
    Blood; 2010 Dec; 116(25):5486-96. PubMed ID: 20805365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Marcucci G; Maharry K; Wu YZ; Radmacher MD; Mrózek K; Margeson D; Holland KB; Whitman SP; Becker H; Schwind S; Metzeler KH; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2010 May; 28(14):2348-55. PubMed ID: 20368543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.
    Yamaguchi S; Iwanaga E; Tokunaga K; Nanri T; Shimomura T; Suzushima H; Mitsuya H; Asou N
    Eur J Haematol; 2014 Jun; 92(6):471-7. PubMed ID: 24443894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.
    Ho PA; Alonzo TA; Kopecky KJ; Miller KL; Kuhn J; Zeng R; Gerbing RB; Raimondi SC; Hirsch BA; Oehler V; Hurwitz CA; Franklin JL; Gamis AS; Petersdorf SH; Anderson JE; Reaman GH; Baker LH; Willman CL; Bernstein ID; Radich JP; Appelbaum FR; Stirewalt DL; Meshinchi S
    Leukemia; 2010 May; 24(5):909-13. PubMed ID: 20376086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation].
    Wang RX; Wu DP; Chen SN; He J; Xu Y; Wang XL; Yin J; Tian H; Tian XP; Sun AN
    Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(10):751-5. PubMed ID: 23755812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
    Brunner AM; Neuberg DS; Wander SA; Sadrzadeh H; Ballen KK; Amrein PC; Attar E; Hobbs GS; Chen YB; Perry A; Connolly C; Joseph C; Burke M; Ramos A; Galinsky I; Yen K; Yang H; Straley K; Agresta S; Adamia S; Borger DR; Iafrate A; Graubert TA; Stone RM; Fathi AT
    Cancer; 2019 Feb; 125(4):541-549. PubMed ID: 30422308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
    Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
    J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome.
    Mason EF; Kuo FC; Hasserjian RP; Seegmiller AC; Pozdnyakova O
    Am J Hematol; 2018 Aug; 93(4):504-510. PubMed ID: 29274134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High IDH1 expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia.
    Ma QL; Wang JH; Wang YG; Hu C; Mu QT; Yu MX; Wang L; Wang DM; Yang M; Yin XF; Chen FF; Lu SS; Chen J; Zhu ZJ; Chen SJ; Jin J
    Int J Cancer; 2015 Sep; 137(5):1058-65. PubMed ID: 25523507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients.
    Aref S; Kamel Areida el S; Abdel Aaal MF; Adam OM; El-Ghonemy MS; El-Baiomy MA; Zeid TA
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):550-5. PubMed ID: 26189213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
    Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
    Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia.
    Kövy P; Őrfi Z; Bors A; Kozma A; Gopcsa L; Dolgos J; Lovas N; Harasztdombi J; Lakatos V; Király Á; Mikala G; Vályi-Nagy I; Reményi P; Andrikovics H
    PLoS One; 2021; 16(6):e0253386. PubMed ID: 34153064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant HIF1- α and SIX-1 Expression is Associated with Poor Prognosis in Acute Myeloid Leukemia Patients with Isocitrate Dehydrogenase 1 Mutations.
    Ali T; Usman R; Shah SA; Parvez A; Anwar S; Muneer Z; Saeed M
    Cancer Control; 2024; 31():10732748241271714. PubMed ID: 39110525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
    Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
    J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation Analysis of IDH1/2 Genes in Unselected De novo Acute Myeloid Leukaemia Patients in India - Identification of A Novel IDH2 Mutation.
    Raveendran S; Sarojam S; Vijay S; Geetha AC; Sreedharan J; Narayanan G; Sreedharan H
    Asian Pac J Cancer Prev; 2015; 16(9):4095-101. PubMed ID: 25987093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients.
    Zhang Y; Wei H; Wang M; Huai L; Mi Y; Zhang Y; Lin D; Liu B; Li W; Zhou C; Rao Q; Wang J
    Leuk Res; 2011 Oct; 35(10):1301-6. PubMed ID: 21316759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.
    Abbas S; Lugthart S; Kavelaars FG; Schelen A; Koenders JE; Zeilemaker A; van Putten WJ; Rijneveld AW; Löwenberg B; Valk PJ
    Blood; 2010 Sep; 116(12):2122-6. PubMed ID: 20538800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Frequency and clinical significance of IDH1 mutations in Chinese acute myeloid leukemia patients.
    Guan L; Gao L; Wang L; Li M; Yin Y; Yu L; Gao C
    PLoS One; 2013; 8(12):e83334. PubMed ID: 24376688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [IDH1 Gene Mutation and Its Clinical Significance in patients with Acute Myeloid Leukemia].
    Wei JF; Qiu HY; Chen GH; Wang Y; Chen Z; Liu HJ; Mao JP; Jia T; Xue LG; Cai ZM; Zhu YX; Zhao LD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1252-7. PubMed ID: 26524018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.